CARM (carismatx.com) Net Profit

CARM (carismatx.com) - company brandmark

Carisma Therapeutics (CARM) focuses on creating innovative CAR-macrophages to combat cancerous tumors. The company's net income level demonstrates current development dynamics, where -0.05 expresses the latest metric level. Breakthrough methods for penetrating solid neoplasms open new therapeutic horizons, while optimized biomaterial supply channels ensure the stability of scientific research.

CARM (Carisma Therapeutics) Net Profit history from 04/28/2023 to 10/25/2025

Analytical breakdowns and data insights for company carismatx.com (CARM)

- price and consensus price forecast:
Stock Quotes Carisma Therapeutics Inc.|CARM - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization CARM|CARM - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Carisma Therapeutics|CARM - Book Capitalization|Market Capitalization to Book Value carismatx.com|CARM - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Carisma Therapeutics|CARM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Carisma Therapeutics Inc.|CARM - Company Total Debt|Debts to Book Capitalization CARM|CARM - Company Long-Term Debt|Company Short-Term Indebtedness Carisma Therapeutics|Immediate Liquidity carismatx.com
- net income and valuation multiples indicators:
CARM - Net Profit
Summary company analysis:Carisma Therapeutics
Core merchandise of Carisma Therapeutics Inc

To protect capital from volatility, it is crucial for investors to distinguish systemic income from one-off anomalies that may distort fundamental valuation. Because Carisma Therapeutics (CARM) utilizes internal development of CAR-M formulas while outsourcing production, the company's profit history serves as a key tool for analyzing real operational efficiency, allowing this chart's dynamics to determine business sustainability and prevent the unjustified freezing of assets during local downturns.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|Intrexon - Net Profit|Pharming Corp (PHAR) - Net Income|NKTR: Net Profit|upstreambio.com (UPB) - Net Profit|Company Net Income Zenas Biopharma|IMNM: Final Profit|Net Profit GOSS|Net Financial Result KalVista Corp|Company Net Income Septerna Inc SEPN|Net Financial Result pieris.com (PVLA)|SVRA - Company Net Income|Rigel Pharma (RIGL) - Net Income|ANAB: Net Profit|Astria Corp (ATXS) - Net Profit|Net Income ENGN|RAPT: Final Profit|Net Income JBIO (Aerovate Therapeutics Inc)|Profit After Payment of Taxes ACRS|Net Profit KYTX (Kyverna)|Final Profit TLSA|Cabaletta Bio, Inc. - Net Profit|Company Net Income ventyxbio.com|Theratechnologies (THTX) - Company Net Income|Avalo Therapeutics, Inc. - Final Profit|ELDN (Eledon) - Net Profit|Net Profit Agenus, Inc|Company Net Income Climb Bio Inc (CLYM)|ZURA: Profit After Tax|Net Profit ATYR (aTyr Pharma)|Adagene Inc (ADAG) - Company Net Income|IMA: Net Income|STTK - Net Profit|EQ (equilliumbio.com) - Net Income|CNTB: Profit After Payment of Taxes|IMUX (Immunic Therapeutics) - Net Profit|Atara Biotherapeutics Inc (ATRA) - Net Financial Result|Net Profit IFRX|Net Income X4 Pharmaceuticals, Inc XFOR|Company Net Income Adicet Bio, Inc. ACET|Net Financial Result Celularity Inc (CELU)|INmune Bio - Net Profit|Barinthus Biotherapeutics PLC (BRNS) - Net Income|KZR: Net Profit|SAB Biotherapeutics Inc (SABS) - Net Profit|Company Net Income Akari Therapeutics|ENLV: Final Profit|Company Net Income Q32 Bio Inc. (QTTB)|Net Income GeoVax Labs GOVX|Company Net Income Edesa EDSA|IBIO (iBio Corporation) - Profit After Tax|XTL Biopharmaceuticals - Net Profit|Final Profit BOLT (Bolt Biotherapeutics)|HCWB: Net Profit|Aptevo Therapeutics Inc. (APVO) - Net Profit|Company Net Income AIM ImmunoTech|ADTX: Final Profit|Company Net Income GRI Bio, Inc. (GRI)|Net Income xortx.com XRTX|Net Profit HIND (Vyome Holdings)|Net Profit Revelation Biosciences Inc REVB|INDP: Net Income|Final Profit SCNI (BiondVax Pharmaceuticals)|CALI: Net Profit|AFMD - Net Financial Result|Company Net Income Allakos Inc|Net Income HOOKIPA (HOOK)|Company Net Income IGM Biosciences, Inc. (IGMS)|Net Income iTeos Pharma ITOS|Ocean Biomedical, Inc. - Net Income|Net Profit tcbiopharm.com TCBP|THRD - Company Net Income